Putting evidence-based medicine into clinical practice: Comparing anti-resorptive agents for the treatment of osteoporosis

Current Medical Research and Opinion

Volumn 20, Issue 4, 2004, Pages 525-531

  Wehren, Lois E ^a,c   Hosking, David ^b   Hochberg, Marc C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c NONE   (United States)

Author keywords

Adjusted indirect comparison; Anti resorptive agents; Efficacy; Meta analysis; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; ESTROGEN; ETIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID;

CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; INCIDENCE; META ANALYSIS; OSTEOLYSIS; OSTEOPOROSIS; RISK FACTOR; VERTEBRA FRACTURE;

ALENDRONATE; BONE RESORPTION; EVIDENCE-BASED MEDICINE; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; META-ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES;

EID: 1942438548     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003269     Document Type: Conference Paper

References (39)

1. Sackett DL, Rosenberg WMC, Gray JAM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. Br Med J 1996;312:71-2
2. Straus SE, Sackett DL. Using research findings in clinical practice. Br Med J 1998;317:339-42
3. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' guides to the medical literature. XXV. Evidence-based medicine: principles for applying the users' guides to patient care. JAMA 2000;284:1290-96
4. Parfitt AM. Quantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosis. Calcif Tissue Int 1979;28:1-5
5. Ravn P, Fledelius C, Rosenquist C, Overgaard K, Christiansen C. High bone turnover is associated with low bone mass in both pre- and postmenopausal women. Bone 1996;19:291-98
6. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-49
7. Heaney RP, Yates AJ, Santora AC. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res 1997;12:1143-51
8. Hernandez CJ, Beaupre GS, Marcus R, Carter DR. A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment. Bone 2001;29:511-16
9. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover. Consensus of an expert panel. J Clin Densitom 1999;2:323-42
10. Riggs BL, Melton LJI, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996;19(Suppl):197S-201S
11. Cranney A, Wells G, Willan A, et al. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-16
12. Cranney A, Tugwell P, Adachi J, et al. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517-23
13. Cranney A, Tugwell P, Zytaruk N, et al. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524-28
14. Wells G, Tugwell P, Shea B, et al. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:529-39
15. Cranney A, Tugwell P, Zytaruk N, et al. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540-51
16. Cranney A, Guyatt G, Griffith L, et al. IX. Summary of meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-78
17. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91
18. McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. JAMA 2000;283:2829-36
19. Song F, Glenny A-M, Altman DG. Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery. Control Clin Trials 2000;21:488-97
20. Song F, Altman DG, Glenny A-M, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003;326:472-76
21. The Osteoporosis Methodology Group, The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:496-507
22. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guides to the medical literature. XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-77
23. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61
24. Ensrud KE, Thompson DE, Cauley JA, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriatr Soc 2000;48:241-49
25. Klotzbuecher C, Ross P, Landsman P, Abbott T, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39
26. Burger H, van Daele PLA, Algra D, et al. Vertebral deformities as predictors of non-vertebral fractures. Br Med J 1994;309:991-92
27. Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35
28. National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998;8(Suppl 4):S1-S88
29. Oxman AD, Cook DJ, Guyatt GH. Users' guides to the medical literature. VI. How to use an overview. JAMA 1994;272:1367-71
30. Kanis JA, Alexandre J-M, Bone HG, et al. Study design in osteoporosis: a European perspective. J Bone Miner Res 2003;18:1133-38
31. Downs RWJ, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000;85:1783-88
32. Dursin N, Dursin E, Yalcin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract 2001;55:505-09
33. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized placebo-controlled study. Curr Med Res Opin 2003;19:383-94
34. Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX® vs EVISTA® Comparison Trial) Intern J Inter Med 2004;255 (in press)
35. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000;85:720-26
36. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289:2525-33
37. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the Early Postmenopausal Intervention Cohort Study. Ann Intern Med 1999;131:935-42
38. Hochberg MC, Greenspan SL, Wasnich RD, Miller PD, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-92
39. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-36